GSS
Director Trades
| Date | Director | Value |
|---|---|---|
| 15/12/24 | M. Aicher | $50,000 |
Company News
Genetic Signatures Reports Regional Success of EasyScreen Gastrointestinal Parasite Detection Kit
Genetic Signatures (ASX: GSS) has reported a strong start to the new financial year with the commercial success of its EasyScreen gastrointestinal parasite detection testing kit across all operating regions, and a 20% increase in sales for the quarter to $5.4 million. Revenue contributions came from new business with existing customers in Australia, which experienced […]
ASX biotech stocks benefiting from the COVID-19 story
Normally investors shun speculative plays in times of market uncertainties, but that’s not been the case with ASX-listed life science stocks across the drug, diagnostics and device sectors. Naturally, the biotechs drawing a connection with fighting or detecting the virus – spurious or otherwise – have seen their valuations soar. Not that investor interest is […]
Genetic Signatures applies to market coronavirus test kit throughout UK and EU
Molecular diagnostics company Genetic Signatures (ASX: GSS) has submitted a European CE in vitro diagnostics registration application for its new 3base EasyScreen coronavirus detection kit. The kit complements the company’s existing EasyScreen respiratory pathogen detection kit which identifies 14 common respiratory pathogens including influenza A and B, rhinovirus and M. pneumoniae and allows a large […]
Genetic Signatures receives green light to market pathogen detection kit in Europe
Molecular diagnostics company Genetic Signatures (ASX: GSS) has received CE-IVD registration, paving the way for the sale of its “EasyScreen” Respiratory Pathogen Detection Kit in Europe. The detection kit can identify 14 common respiratory pathogens, including Influenza A & B, Rhinovirus and M. pneumoniae. The kit allows for rapid detection of pathogens in up to […]
Genetic Signatures secures ‘major’ sales contract for EasyScreen respiratory technology
Molecular diagnostics company Genetic Signatures (ASX: GSS) has announced a major new contract with a large Australian pathology service provider and release of two new products. Genetic Signatures secured the contract with an Australian pathology service provider and expects its new customer to conduct as many as 1,000 tests per day, depending on the severity […]
Genetic Signatures receives approval to market superbug detection kits in Australia
Molecular diagnostics company Genetic Signatures (ASX: GSS) has received Therapeutic Goods Administration (TGA) registration, thereby allowing the sale of its novel “Extended Spectrum Beta-Lactamase and Carbapenemase Producing Organisms” (ESBL & CPO) detection kit in Australia. This follows the company’s receipt of European approval last month which enabled the sale of the ESBL & CPO products […]